Articles

Treatment with ocrelizumab can improve freedom from individual events in patients with relapsing-remitting multiple sclerosis regardless of suboptimal DMT response in the past. 

Ocrelizumab Holds Benefit for Relapsing MS Patients With Prior Suboptimal DMT Response

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

The Importance of Patient-Centered Care in Parkinson Disease

Videos

The director of the UCSF Weill Institute for Neuroscience offered his perspective on data presented at MS Virtual suggesting ofatumumab’s benefit in patients with MS who were treatment naïve.

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other. 

Progressive and Relapsing-Remitting Multiple Sclerosis Share Similar Fatigue Severity

In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.

World Alzheimer’s Day 2020: The Latest News and Commentary on the Treatment of Alzheimer Disease 

Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy. 

Optimal Management of OFF Episodes in Parkinson's Disease

David Dodick, MD, reviews changes to the treatment landscape for acute migraine. 

The Changing Treatment Landscape for Acute Migraine

The neurologist at Mayo Clinic shares his thoughts on the state of Alzheimer disease awareness and what can be done to lower dementia rates. 

Jonathan Graff-Radford, MD: Efforts to Reduce Rates of Alzheimer Disease Dementia

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

All News

New content coming soon, please check back later.